Obeticholic Acid for Prevention in Barrett's Esophagus

Research Group
Gastrointestinal and Other Cancers
Sponsor
National Cancer Institute (NCI)
Status
Recruiting
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT04939051
This phase II trial studies the effect of obeticholic acid in treating patients with Barrett's esophagus. Bile acids present in duodenogastroesophageal reflux contribute to neoplastic progression in Barrett's esophagus. Obeticholic acid has shown anti-cholestatic, anti-inflammatory and anti-fibrotic effects mediated by FXR activation. It down regulates bile acid availability and decreases proinflammatory cytokine production including IL-1β and TNFα in human enterocytes and immune cells. This chain of events reduces the bile acid exposure in esophagus tissue thereby limiting bile acid induced damage and dysplastic progression.
Intervention
Placebo Administration, Obeticholic Acid, Esophageal Biopsy, Liver Ultrasonographic Elastography, Biospecimen Collection, Esophagogastroduodenoscopy, Questionnaire Administration
Condition
Barrett Esophagus
Investigators
Dean E Brenner, Nicholas J. Shaheen, Ajay Bansal, Dayna S. Early, Joseph E. Willis, Prashanthi Thota, Amitabh Chak

See list of participating sites